NUCLEOLIN and breast cancer: In another work, we have also designed a F3 peptide-targeted liposomal strategy, involving sterically stabilized pH-sensitive liposomes targeting the cell surface nucleolin, and exploited its potential for delivery of doxorubicin (DXR) to cancer cells and the tumor microenvironment (endothelial cells) in breast cancer, with similar success [154].